In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Indaptus Therapeutics (INDP – Research Report), with a price target of $2.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jason McCarthy has given his Buy rating due to a combination of factors related to Indaptus Therapeutics’ promising clinical developments and strategic approach. The company has made significant progress with its Decoy20 platform, which is designed to stimulate the immune system against advanced solid tumors. The initiation of the P1b/2 trial combining Decoy20 with the anti-PD1 therapy, tislelizumab, marks a critical step forward, as early indications suggest that the combination is safe and well-tolerated.
Moreover, the trial’s design, which includes sequential patient enrollment and monitoring, ensures a thorough evaluation of safety and efficacy. The positive safety profile observed in previous studies, along with the potential to prime the immune system for anti-tumor activity, enhances the platform’s attractiveness. McCarthy’s valuation model, which considers multiple cancer indications and applies risk adjustments, supports a favorable price target, reinforcing the Buy rating.
INDP’s price has also changed dramatically for the past six months – from $1.000 to $0.340, which is a -66.00% drop .